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Cirrhosis is not a contraindication to
cytoreductive surgery and hyperthermic
intraperitoneal chemotherapy in highly
selected patients
Anna Weiss, Erin P. Ward, Joel M. Baumgartner, Andrew M. Lowy and Kaitlyn J. Kelly*
Abstract
Background: Patient selection for cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy
(HIPEC) is critically important to optimizing outcomes. There is currently no literature regarding the safety of
CRS/HIPEC in patients with cirrhosis. The aim of this case series is to report the outcomes of three patients
with well-compensated cirrhosis who underwent CRS/HIPEC.
Methods: Patients were identified from a prospectively maintained peritoneal surface malignancy database. Patient,
tumor, and operative-related details were recorded as short-term postoperative outcomes. Results were analyzed using
descriptive statistics.
Results: All patients had well-compensated (Child-Pugh Class A) cirrhosis and Eastern Cooperative Oncology Group
(ECOG) performance status of 0. One patient had preoperative evidence of portal hypertension. All safely underwent
CRS/HIPEC with completeness of cytoreduction (CC) scores of 0. The postoperative morbidity profile was unique, but
all complications were manageable and resulted in full recovery to preoperative baseline status.
Conclusions: Patient selection for CRS/HIPEC is critical for optimization of short- and long-term outcomes. This small
series suggests that well-compensated cirrhosis should not be an absolute contraindication to CRS/HIPEC.
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Background
Cytoreductive surgery (CRS) and hyperthermic intraperi-
toneal chemotherapy (HIPEC) is now widely accepted as
the standard of care for peritoneal surface malignancy
(PSM) from appendiceal, colorectal, and primary peri-
toneal malignancies. Cytoreductive surgery alone may
carry a high risk of morbidity even without considering
the addition of HIPEC. Postoperative morbidity rates for
CRS/HIPEC are reported between 40 and 52%, and
major morbidity at 17–24% [1–8]. In-hospital mortality
varies from 0 to 4.4% and 30-day mortality from 2.4 to
8% [1–4, 9]. Reoperation rates are as high as 15–17.5%,
and length of stay has been reported to be between 8
and 16 days on average. [1–3, 9, 10]
Multiple studies have evaluated outcomes of non-
hepatic surgery in patients with cirrhosis [11]. In general,
rates of postoperative morbidity and mortality are higher
in cirrhotic patients following major intraabdominal sur-
geries than for non-cirrhotic patients undergoing similar
procedures. For example, El Nakeeb and colleagues re-
ported statistically significantly higher rates of wound
complications, intraabdominal hemorrhage, pancreatic
fistula, and hospital mortality in cirrhotic patients than
non-cirrhotics following pancreaticoduodenectomy [12].
The authors concluded that the operation should only
be performed in patients with well-compensated cirrho-
sis—those with Child-Pugh class A disease, and no
portal hypertension. In a series of 772 patients with cir-
rhosis undergoing major surgery, several factors affected
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outcome—age, American Society of Anesthesiology
(ASA) class, and model for end-stage liver disease
(MELD) score were found to predict mortality at 30 and
90 days postoperatively, independent of the procedure
performed [13]. Risks of elective major surgery were low
in patients with a MELD score of less than 11. Risks
were so high in those with a MELD score of ≥ 20; it was
recommended that all elective procedures be postponed
until after liver transplantation. In patients with an inter-
mediate MELD score of 12 to 19, it was recommended
that evaluation for transplantation be completed prior to
elective major surgery so that transplant could be expe-
dited postoperatively if required. [13]
CRS/HIPEC has never been examined in patients with
cirrhosis. While patients with cirrhosis are known to
have increased risk of morbidity and mortality following
laparotomy, there are theoretically no explicit contrain-
dications to CRS/HIPEC, and hepatotoxicity related to
intraperitoneal (IP) agents has not been reported. The
aim of this report is to describe a small series of patients
with Child-Pugh class A cirrhosis who safely underwent
CRS/HIPEC.
Methods
Patients
A retrospective analysis of a prospectively maintained
peritoneal surface malignancy database from a single,
high-volume CRS/HIPEC center was completed. It was
noted that within the past 2 years, several patients with
known cirrhosis presented for evaluation for CRS/
HIPEC. Three individuals with cirrhosis who underwent
CRS/HIPEC were identified in the Research Electronic
Data Capture (REDCap) software-based database and
reviewed. This prospectively maintained REDCap data-
base is maintained in accordance with our institutional
review board.
Data
Preoperative, operative, and postoperative data for all
three patients was evaluated. Preoperative variables
included general demographics, past medical history,
histologic diagnosis, Eastern Cooperative Oncology
Group (ECOG) performance status, body mass index
(BMI), pre-operative symptoms, etiology of cirrhosis, la-
boratory values, Child-Pugh score, MELD score, and
prior treatment for cirrhosis. Operative variables col-
lected included peritoneal carcinomatosis index (PCI),
cytoreductive procedures performed, operative time,
estimated blood loss (EBL), urine output, intraoperative
transfusion, HIPEC agent, and completeness of cytore-
duction (CC) score. Postoperative variables collected in-
cluded intensive care unit (ICU) length of stay (LOS)
and total hospital admission LOS, time to return of
bowel function defined as first flatus, postoperative
transfusion, 30-day morbidity, serum bilirubin at dis-
charge, international normalized ratio (INR) at dis-
charge, and platelet count at discharge. Complications
were classified per the Clavien system [14]. Patient-
specific data and outcomes were analyzed with descrip-
tive statistics.
Surgery
In all cases, a laparoscopy was performed prior to the
definitive procedure for assessment of disease burden
and candidacy for definitive CRS/HIPEC without associ-
ated complications. At time of laparotomy, the periton-
eal surfaces were systematically inspected and the small
bowel was examined from the ligament of Treitz to the
ileocecal valve. The PCI as defined by Sugarbaker was
determined, and assessment of potential complete cytor-
eduction (CC 0 or 1) and removal of all gross disease
was completed [15]. CRS/HIPEC was performed utiliz-
ing our standardized methods as previously described
[16]. The intraperitoneal chemotherapy solution was
heated to 42 °C and infused for 90 min, as is the stand-
ard approach. This was not changed for these cirrhotic
patients.
Results
Two Caucasian male patients and one Hispanic female
were identified. The median age of the patients was
49 years (range 44 to 59), and patient BMI ranged from
24 to 37 kg/m2 (median 32). The two male patients
presented with low-grade appendiceal mucinous neo-
plasm (LAMN) and the female patient presented with
peritoneal mesothelioma. Two patients denied symp-
toms at presentation, and one presented with isolated
right lower quadrant abdominal pain. Both asymptom-
atic patients were initially diagnosed with peritoneal
pathology found incidentally on cross-sectional imaging
completed for liver disease. All patients underwent a
baseline laparoscopy prior to CRS/HIPEC for assessment
of disease burden prior to laparotomy. One patient had
the initial assessment during a laparoscopic right hemi-
colectomy at a referring institution. The etiology of cir-
rhosis included hepatitis C for two patients and alcohol
for the other. All patients had normal hepatic function
at baseline (Child-Pugh Class A), one had ascites at
presentation, and one had sequelae of portal hyperten-
sion. Demographic and baseline clinical characteristics
are summarized in Table 1.
All patients underwent open CRS/HIPEC with
complete clearance of all gross disease (CC 0). The me-
dian PCI was 9 (range 6 to 12). Procedures performed
included omentectomy, selective peritonectomy includ-
ing liver surface, excision of bowel nodules with serosal
repair, ileocecectomy, hysterectomy, and oophorectomy.
Operative time ranged from 306 to 463 min (median
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368). The median estimated blood loss was 200 mL
(range 200 to 500) and median urine output was
675 mL (range 500 to 880). One patient received an
intraoperative blood transfusion (2 units). HIPEC
was performed with mitomycin C (30 to 40 mg) for
the patients with LAMN, and with cisplatin
(182 mg) and doxorubicin (27 mg) for the patient
with peritoneal mesothelioma. Operative data are
summarized in Table 2.
Postoperatively, the median length of ICU and overall
hospital stay were 1 and 13 days, respectively. The me-
dian time to return of bowel function was 4 days (range
4 to 6). All patients experienced a postoperative morbid-
ity within 30 days. Two patients who did not have asci-
tes preoperatively developed symptomatic ascites in the
postoperative period. These patients were managed with
paracentesis, spironolactone, and sodium restriction. In
one case, the ascites fluid became infected and treatment
Table 1 Preoperative patient and tumor-related variables
Patient 1 Patient 2 Patient 3
Age (years) 49 59 44
Gender M M F
Disease type LAMN LAMN with focal high grade Malignant mesothelioma
ECOG 0 0 0
ASA class III III IV
BMI (kg/m2) 37 24 32
Symptoms None None (right lower quadrant pain
prompted laparoscopic appendectomy
turned right hemicolectomy)
Weight loss, abdominal distension,
lower extremity edema
Etiology of cirrhosis HCV Alcohol HCV cirrhosis, GT1a
Bilirubin 0.5 0.51 0.3
INR 1.2 1.1 1.0
Ascites (yes/no) No No Yes
Child’s class A A A
Platelet count 164 207 259
Portal hypertension No Yes No
MELD score 8 8 6
Treatment for hepatitis
C/cirrhosis
None Alcohol cessation, propranolol for gastric
varices
None
Other significant PMH HTN, non-insulin-dependent diabetes None Insulin-dependent diabetes
ECOG Eastern Cooperative Oncology Group, ASA American Society of Anesthesiology, BMI body mass index, INR international normalized ratio, MELD model for
end-stage liver disease, PMH past medical history
Table 2 Operative variables
Patient 1 Patient 2 Patient 3
Date 2/16/2011 2/17/2015 7/10/2015
PCI 12 6 9
Epidural (yes/no) No No Yes
Procedures performed Excision of tumors on sigmoid
colon and cecum, pelvic
peritonectomy, liver wedge
biopsy, omentectomy
Omentectomy, selective
peritonectomy, ventral
hernia repair
Diagnostic laparoscopy, Omentectomy,
extensive peritonectomy, including bilateral
diaphragms, ileocecectomy with primary
anastomosis, hysterectomy, left oophorectomy
Operative time (min) 306 463 368
Estimated blood loss (cm3) 200 200 500
Urine output (cm3) 500 675 880
Need for transfusion No No Yes (2 units PRBC, 1 unit FFP)
HIPEC agent 30 mg mitomycin C 40 mg mitomycin C 182 mg cisplatin, 27 mg doxorubicin
CC score 0 0 0
PCI Peritoneal Cancer Index, CC completeness of cytoreduction, HIPEC hyperthermic intraperitoneal chemotherapy
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with IV antibiotics was required. Additional complica-
tions included urinary tract infection, ileus, and one
superficial wound infection. No patients developed la-
boratory evidence of hepatic insufficiency postopera-
tively, and no patients developed long-term sequelae
(repeated paracentesis after discharge, for example) of
hepatic insufficiency. Postoperative data are summarized
in Table 3. The two patients with LAMN are both clinic-
ally No Evidence of Disease (NED) at 6 and 46 months
from the date of CRS/HIPEC. The patient with periton-
eal mesothelioma remains clinically NED at 15 months
following CRS/HIPEC.
Discussion
CRS/HIPEC carries significant morbidity, but despite the
known risks, it remains the standard of care for periton-
eal surface malignancy including appendiceal, colorectal,
and primary peritoneal tumors [15, 17–19]. CRS/HIPEC
allows for a uniquely effective treatment for diseases that
otherwise have limited safe, systemic-based chemother-
apy options. The use of direct IP administration of
chemotherapy during HIPEC allows for markedly higher
drug delivery to peritoneal-based tumors than can be
safely achieved with systemic administration [10]. The IP
administration allows patients to gain the benefits of
high drug concentration while minimizing the risk of
systemic toxicity associated with the commonly used
drugs. Currently, the most common side effects of IP ad-
ministration of HIPEC agents at the time of CRS include
ileus, acute kidney injury, neutropenia, impaired wound
healing, and anastomotic dehiscence [7, 20].
As careful patient selection for CRS/HIPEC is critical
to optimize outcomes, recent research efforts have in-
vestigated the safety of CRS/HIPEC in specific patient
populations, such as the elderly and the morbidly obese
[16, 21–23]. These studies have served to better define
which patients are eligible for treatment, and to allow
for more informed discussions about the expected post-
operative course in these specific patient populations.
Alyami and colleagues reported that patients greater
than 70 years of age undergoing CRS/HIPEC had signifi-
cantly more cardiovascular complications than younger
patients, but had no significant difference in 90-day
overall morbidity or mortality [21]. Obesity has been
shown to be associated with increased risk of renal, pul-
monary, and wound complications following CRS/
HIPEC, but has not been associated with serious mor-
bidity or mortality [16, 22]. Several groups have con-
cluded that obesity should not even be a relative
contraindication to treatment [24]. To date, there have
been no previous reports of CRS/HIPEC being per-
formed in patients with cirrhosis, a growing subset of
the population with a unique comorbidity profile [11].
In the current case series, we identified three cirrhotic
patients that were successfully treated with CRS/HIPEC,
although not without some complication. Two of the
three patients who did not have ascites preoperatively
developed serous ascites in the postoperative setting.
Both cases were successfully managed with diuresis and
sodium restriction. In contrast, the patient with periton-
eal mesothelioma that did have serous ascites preopera-
tively had complete resolution of ascites after CRS/
HIPEC. This patient’s paracentesis preoperatively
showed “atypical mesothelial cell proliferation,” suggest-
ing that the fluid was related to malignancy and not to
underlying liver disease. These findings suggest that ser-
ous ascites in patients presenting with cirrhosis and
PSM may be secondary to either etiology. Cirrhosis-
related ascites significantly impacts Child’s score and
perceived operative risk and some consider ascites a
Table 3 Postoperative variables
Patient 1 Patient 2 Patient 3
ICU length of stay (days) 1 1 2
Length of stay (days) 22 7 13
Time to NG or g-tube removal (days) None placed None placed 2
Time to first flatus (days) 4 4 6
Need for postoperative blood transfusion None None None
30-day morbidity/gradea UTI/II
Ascites/II
SBP/II
Ileus/II
Ascites/II Superficial site infection/I
Bilirubin on discharge 1.1 0.63 0.75
INR on discharge 1.4 1.5 1.1
Platelet count on discharge 76 132 430
Final pathology Acellular mucin, liver biopsy—cirrhosis LAMN, acellular mucin Epithelioid type mesothelioma
ICU intensive care unit, INR international normalized ratio
aClavien-Dindo classification
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contraindication to CRS/HIPEC in PSM of colorectal
origin; however, ascites may be the result of the patient’s
peritoneal malignancy presenting a unique diagnostic
quandary. Our findings support performing paracentesis
with analysis of fluid for electrolytes and protein, and
cytology should be considered to determine the etiology
of ascites prior to excluding patients based solely on the
presence of ascites. Similarly, postoperative ascites may
not reflect recurrent disease but may be cirrhosis
related. This was the case for one of the patients in this
study with LAMN. Preoperatively, the patient had
mucinous implants on his peritoneum and omental
thickening but no ascites. Six months postoperatively, he
developed serous ascites (Fig. 1a, b), but paracentesis
revealed fluid cytology without mucin or malignant cells
and his ascites ultimately resolved with sodium restric-
tion and diuresis.
Many features of CRS/HIPEC make it unique relative
to other major abdominal surgeries. These include the
administration of hyperthermia and IP chemotherapy,
the likelihood of prolonged operative time and accom-
panying significant fluid shifts. Patients in this study
received either MMC or cisplatin/doxorubicin as HIPEC
agents. MMC is a cytotoxic antibiotic derived from
fungus that acts by cross-linking DNA and has wide
anti-tumor activity. The most common systemic toxic-
ities are myelosuppression, nephrotoxicity, and pulmon-
ary fibrosis. Cisplatin is a platinum-based compound,
and the most common systemic toxicities associated
with cisplatin are nephrotoxicity, mild peripheral neur-
itis, nausea and vomiting, and ototoxicity [25]. Doxo-
rubicin is cleared predominantly by the liver, and the
most common systemic toxicities are myelotoxicity, mu-
cositis, alopecia, and cardiomyopathy [25]. None of these
agents are associated with hepatotoxicity with systemic
administration. It is therefore unlikely that they would
cause hepatotoxicity with IP administration.
One factor that could theoretically lead to liver dys-
function in cirrhotic patients undergoing CRS/HIPEC is
prolonged operative time and prolonged exposure to
general anesthesia. In this series, the longest procedure
was 463 min. CRS/HIPEC cases for patients with exten-
sive peritoneal disease burden can be in excess of 10 to
12 h. It is likely that such extended operative time would
add significant risk for patients with cirrhosis, even if
well compensated.
A significant limitation of this report is the small num-
ber of patients. However, the primary aim of this review
was not to say that all patients with well-compensated
cirrhosis can safely undergo CRS/HIPEC. Rather, our re-
sults demonstrate that CRS/HIPEC can be safely under-
taken in select patients with well-compensated cirrhosis
and describes the baseline and operative characteristics
of three patients that were successfully treated. As pa-
tients with metastatic cancer are not candidates for liver
transplantation, decisions about undergoing major sur-
gery need to be made very carefully in this population.
We recommend extrapolating previous recommenda-
tions for elective major surgery in cirrhotic patients to
CRS/HIPEC. In the current study, all patients had a
MELD score < 11, which has been shown in a large retro-
spective review of major gastrointestinal, orthopedic, and
cardiovascular operations, to portend a 10% surgical mor-
tality risk [13]. Considering the nuances of CRS/HIPEC
specifically, we recommend consideration of the estimated
operative time, disease burden, and overall cancer progno-
sis in determining if patients with cirrhosis are candidates
for surgery. Patients with LAMN are able to achieve long-
term survival following complete cytoreduction and
HIPEC with CC 0 or 1 cytoreduction [1, 26]. Those with
colorectal cancer or peritoneal mesothelioma, however,
should only be selected if they have limited disease burden
and CC 0 cytoreduction can be achieved [27]. Addition-
ally, patients presenting with ascites should have fluid
Fig. 1 a Preoperative computed tomography scan of a patient with pseudomyxoma peritonei from low-grade appendiceal mucinous neoplasm
with cirrhosis. Arrow shows mucinous implants on the peritoneal surface of the right hemi-diaphragm. b Magnetic resonance imaging scan at
6 months postoperatively showing diffuse ascites. This fluid was removed by paracentesis and was serous. Cytology was negative for mucin or
malignant cells, and the ascites was resolved with sodium restriction and diuresis
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studies to determine if it is related to malignancy or
liver disease. We recommend selection of non-
hepatotoxic drugs for IP therapy in cirrhotic patients
and early hepatology consultation for perioperative
management.
Conclusions
Patient selection for CRS/HIPEC is critical for optimization
of short- and long-term outcomes for all patients. This
report will hopefully provide some initial framework for
clinicians encountering patients with cirrhosis and PSM
and motivate others to similarly report their experience
with this challenging patient population to allow for larger
studies to be performed in the future.
Abbreviations
ASA: American Society of Anesthesiology; BMI: Body mass index;
CC: Completeness of cytoreduction; CRS: Cytoreductive surgery;
EBL: Estimated blood loss; ECOG: Eastern Cooperative Oncology Group;
HIPEC: Hyperthermic intraperitoneal chemotherapy; ICU: Intensive care unit;
INR: International normalized ratio; IP: Intraperitoneal; LAMN: Low-grade
appendiceal mucinous neoplasm; LOS: Length of stay; MELD: Model for
end-stage liver disease; NED: No Evidence of Disease; PCI: Peritoneal
carcinomatosis index; PSM: Peritoneal surface malignancy; REDCap: Research
Electronic Data Capture
Availability of data and materials
The datasets generated and/or analyzed during the current study are not
publicly available due to the presence of protected health information
within the dataset, but are available from the corresponding author in a de-
identified fashion on reasonable request.
Authors’ contributions
All authors of this paper participated directly in the planning, execution,
and/or analysis of the study and have read and approved the final submitted
version.
Ethics approval and consent to participate
The creation of the REDCap database for all HIPEC patients seen at UCSD
operates under UCSD Institutional Review Board approval. Patients are
consented at the time of presentation to UCSD for inclusion. The IRB
approval number is 140754.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published
maps and institutional affiliations.
Received: 11 January 2018 Accepted: 16 April 2018
References
1. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al.
Early- and long-term outcome data of patients with pseudomyxoma
peritonei from appendiceal origin treated by a strategy of cytoreductive
surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;
30:2449–56.
2. Elias D, Gilly F, Quenet F, Bereder JM, Sideris L, Mansvelt B, et al.
Pseudomyxoma peritonei: a French multicentric study of 301 patients
treated with cytoreductive surgery and intraperitoneal chemotherapy. Eur J
Surg Oncol. 2010;36:456–62.
3. Levine EA, Stewart JH 4th, Shen P, Russell GB, Loggie BL, Votanopoulos KI.
Intraperitoneal chemotherapy for peritoneal surface malignancy: experience
with 1,000 patients. J Am Coll Surg. 2014;218:573–85.
4. Lord AC, Shihab O, Chandrakumaran K, Mohamed F, Cecil TD, Moran BJ.
Recurrence and outcome after complete tumour removal and hyperthermic
intraperitoneal chemotherapy in 512 patients with pseudomyxoma
peritonei from perforated appendiceal mucinous tumours. Eur J Surg Oncol.
2015;41:396–9.
5. Tabrizian P, Shrager B, Jibara G, Yang MJ, Romanoff A, Hiotis S, et al.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for
peritoneal carcinomatosis: outcomes from a single tertiary institution. J
Gastrointest Surg. 2014;18:1024–31.
6. Vaira M, Cioppa T, De Marco G, Bing C, D'Amico S, D'Alessandro M, et al.
Management of pseudomyxoma peritonei by cytoreduction+HIPEC
(hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-
year experience. In Vivo. 2009;23:639–44.
7. Baumgartner JM, Kwong TG, Ma GL, Messer K, Kelly KJ, Lowy AM. A novel tool
for predicting major complications after cytoreductive surgery with
hyperthermic intraperitoneal chemotherapy. Ann Surg Oncol. 2016;23:1609–17.
8. Elias DM, Sideris L. Pharmacokinetics of heated intraoperative intraperitoneal
oxaliplatin after complete resection of peritoneal carcinomatosis. Surg
Oncol Clin N Am. 2003;12:755–69. xiv
9. Van der Speeten K, Govaerts K, Stuart OA, Sugarbaker PH. Pharmacokinetics
of the perioperative use of cancer chemotherapy in peritoneal surface
malignancy patients. Gastroenterol Res Pract. 2012;2012:378064. https://doi.
org/10.1155/2012/378064.
10. Katz MH, Barone RM. The rationale of perioperative intraperitoneal
chemotherapy in the treatment of peritoneal surface malignancies. Surg
Oncol Clin N Am. 2003;12:673–88.
11. de Goede B, Klitsie PJ, Lange JF, Metselaar HJ, Kazemier G. Morbidity and
mortality related to non-hepatic surgery in patients with liver cirrhosis: a
systematic review. Best Pract Res Clin Gastroenterol. 2012;26:47–59.
12. El Nakeeb A, Sultan AM, Salah T, El Hemaly M, Hamdy E, Salem A, et al.
Impact of cirrhosis on surgical outcome after pancreaticoduodenectomy.
World J Gastroenterol. 2013;19:7129–37.
13. Teh SH, Nagorney DM, Stevens SR, Offord KP, Therneau TM, Plevak DJ, et al.
Risk factors for mortality after surgery in patients with cirrhosis.
Gastroenterology. 2007;132:1261–9.
14. Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al.
The Clavien-Dindo classification of surgical complications: five-year
experience. Ann Surg. 2009;250:187–96.
15. Sugarbaker PH, Yan TD, Stuart OA, Yoo D. Comprehensive management of
diffuse malignant peritoneal mesothelioma. Eur J Surg Oncol. 2006;32:686–91.
16. Polanco PM, Sanchez AI, Ramalingam L, Jones H, Zureikat A, Holtzman M, et
al. Does obesity affect outcomes of cytoreductive surgery and hyperthermic
intraperitoneal chemoperfusion for disseminated mucinous appendiceal
neoplasms? Ann Surg Oncol. 2014;21:3963–9.
17. Mohamed F, Cecil T, Moran B, Sugarbaker P. A new standard of care for the
management of peritoneal surface malignancy. Curr Oncol. 2011;18:e84–96.
18. Yan TD, Black D, Savady R, Sugarbaker PH. Systematic review on the efficacy
of cytoreductive surgery combined with perioperative intraperitoneal
chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J
Clin Oncol. 2006;24(24):4011–9.
19. Yan TD, Black D, Savady R, Sugarbaker PH. A systematic review on the efficacy
of cytoreductive surgery and perioperative intraperitoneal chemotherapy for
pseudomyxoma peritonei. Ann Surg Oncol. 2007;14:484–92.
20. Van der Speeten K, Stuart OA, Sugarbaker PH. Pharmacology of
perioperative intraperitoneal and intravenous chemotherapy in patients
with peritoneal surface malignancy. Surg Oncol Clin N Am. 2012;21:577–97.
21. Alyami M, Lundberg P, Kepenekian V, Goere D, Bereder JM, Msika S, et al.
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for
peritoneal carcinomatosis in the elderly: a case-controlled, multicenter
study. Ann Surg Oncol. 2016;23(Suppl 5):737–45.
22. Neuwirth MG, Bartlett EK, Roses RE, Fraker DL, Kelz RR, Karakousis GC.
Obesity is not associated with increased morbidity in patients undergoing
cytoreductive surgery with intraperitoneal chemotherapy. J Surg Oncol.
2016;114:619–24.
23. Tabrizian P, Jibara G, Shrager B, Franssen B, Yang MJ, Sarpel U, et al.
Outcomes for cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy in the elderly. Surg Oncol. 2013;22:184–9.
24. Votanopoulos KI, Swords DS, Swett KR, Randle RW, Shen P, Stewart JH, et al.
Obesity and peritoneal surface disease: outcomes after cytoreductive
surgery with hyperthermic intraperitoneal chemotherapy for appendiceal
and colon primary tumors. Ann Surg Oncol. 2013;20:3899–904.
Weiss et al. World Journal of Surgical Oncology  (2018) 16:87 Page 6 of 7
25. Rossi CR, Mocellin S, Pilati P, Foletto M, Quintieri L, Palatini P, et al.
Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol
Clin N Am. 2003;12:781–94.
26. Kelly KJ, Nash GM. Peritoneal debulking/intraperitoneal chemotherapy-non-
sarcoma. J Surg Oncol. 2014;109:14–22.
27. Baumgartner JM, Tobin L, Heavey SF, Kelly KJ, Roeland EJ, Lowy AM.
Predictors of progression in high-grade appendiceal or colorectal peritoneal
carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal
chemotherapy. Ann Surg Oncol. 2015;22:1716–21.
Weiss et al. World Journal of Surgical Oncology  (2018) 16:87 Page 7 of 7
